Swedish based pharmaceutical development company, Kancera, has announced that unique blockers (antagonists) of the Fractalkine system have been patented, laying the foundations for the development of additional drug candidates. Read more


Contract development and manufacturing organisation (CDMO) — Recipharm and Kancera, a development company focused on cancer therapy, have entered into a contract for the development and manufacture of the pharmaceutical candidate KAND567. Read more


Kancera has applied for approval of a Phase I trial for its drug candidate, KAND567, which blocks the fractalkine system. The study will be performed in collaboration with the clinical contract company QPS in the Netherlands. Read more


Kancera reports positive effects demonstrated with its substance, KAND567, in blocking the Fractalkine system. Read more